• Home
  • About
  • Diagnostics
    • AXIM Biotech TearScan
    • Other Areas
      • New Test Development
  • Investors
    • Company Info
    • Press Releases
    • Presentations
    • Corporate Governance
    • FAQ
  • Contact

First-in-Class COVID-19 Rapid Diagnostic Test for Neutralizing Antibodies Could Serve as Immunity Passport for Vaccine Developers

by IR Team | Jul 16, 2020 | News

By LabMedica.com A new rapid diagnostic test for measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells could serve as an ‘Immunity Passport’ for vaccine developers around the world as they begin...

AXIM Biotechnologies unveils rapid test for neutralizing antibodies, files Pre-EUA with the FDA

by IR Team | Jul 16, 2020 | News

By Medical Laboratory Observer AXIM Biotechnologies, an healthcare solutions company focused on oncological research, has announced the development of NeuCovix, a rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent...

First-in-Class COVID-19 Rapid Diagnostic Test for Neutralizing Antibodies Could Serve as Immunity Passport for Vaccine Developers

by IR Team | Jul 16, 2020 | News

By HospiMedica International staff writers Posted on 16 Jul 2020  A new rapid diagnostic test for measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells could serve as an ‘Immunity Passport’ for...
Next Entries »

About

Diagnostics

Investors

Contact

Success!

Subscribe

  • Follow
  • Follow